Exploring the promise of billion-dollar KRAS drugs
In May 2021, when Amgen’s Lumakras (sotorasib) was launched, the milestone was met with great fanfare. Intended for certain patients…
All articles by Abi Millar
Abi Millar
-
-
Decoding the Covid-19 connection with diabetes
Early in the pandemic, it became clear that Covid-19 infection spelt trouble for people with diabetes. While not at greater…
-
The challenges of multiple drugs safety reporting
Polypharmacy – typically defined as taking five or more medications every day – has become a staple of many people’s…
-
Digitising the pharma supply chain
Since the start of the pandemic, the pharmaceutical supply chain has been under scrutiny. Never much of a talking point…
-
The ethics of vaccine boosters
As we head towards the winter, countries around the world are nervously eyeing their rates of Covid-19. If rates were…
-
Living medicines: using bacteria to fight cancer
In the late 19th century, an American bone surgeon named William Coley discovered a surprising pattern: cancer patients who also…
-
Five pharma cybersecurity breaches to know and learn from
At the start of the Covid-19 pandemic, digital adoption increased at a rate never seen before. With lockdowns and physical…
-
Ferring draws closer to a microbiome breakthrough
Clostridium difficile, also known as C. diff, often traps patients in a vicious cycle. A bacterial infection causing persistent diarrhoea…
-
Fighting India’s ‘black fungus’ epidemic
In May, just as the Delta variant of Covid-19 was ripping its way through India, we began to hear reports…
-
Blood plasma production: OK for the UK?
On 7 April, people in the UK were permitted to donate blood plasma for medicines for the first time in…